Different NT-proBNP circulating levels for different types of cardiac amyloidosis

Aim Several studies suggest that the N-terminal fragment of pro-brain natriuretic peptide levels are quite different in wild-type transthyretin (TTR)-related amyloidosis (ATTRwt) and mutated TTR-related amyloidosis (ATTRm) compared with immunoglobulin light-chain cardiac amyloidosis. Our aim was to test this hypothesis in a cohort of patients with different types of cardiac amyloidosis. Patients and methods Seventy patients with ATTRwt, ATTRm, and light-chain cardiac amyloidosis matched for left ventricular (LV) mass index were studied by standard echocardiography, tissue Doppler imaging, and plasmatic cardiac biomarkers. Results Despite similar LV mass and renal function, patients with ATTR cardiac amyloidosis showed lower levels of N-terminal fragment of pro-brain natriuretic peptide than do light-chain amyloidosis ones, especially when expressed as a function of LV mass index. Conclusion Amyloidogenic light-chain-derived fibrils induce more severe myocardial dysfunction in light-chain amyloidosis than in ATTR, despite similar myocardial infiltration. Thus, the degree of cardiac dysfunction may be related not only to the amount of amyloid deposited, but also to qualitative differences among fibrils.

[1]  P. Hawkins,et al.  Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. , 2014, European heart journal cardiovascular Imaging.

[2]  S. Solomon,et al.  Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.

[3]  S. K. White,et al.  Native T1 mapping in transthyretin amyloidosis. , 2014, JACC. Cardiovascular imaging.

[4]  A. Wechalekar,et al.  Imaging in systemic amyloidosis. , 2013, British medical bulletin.

[5]  A. Petrie,et al.  Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome , 2013, Journal of the American Heart Association.

[6]  L. Padeletti,et al.  Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.

[7]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[8]  F. Perfetto,et al.  Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? , 2011, Journal of cardiovascular medicine.

[9]  H. Katus,et al.  Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  R. Falk,et al.  Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. , 2009, American heart journal.

[11]  F. Salvi,et al.  Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.

[12]  O. Cummings,et al.  Biochemical characterisation of amyloid by endomyocardial biopsy , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  P. Lindqvist,et al.  Do troponin and B‐natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? , 2008, Journal of internal medicine.

[14]  F. Salvi,et al.  Gender-related risk of myocardial involvement in systemic amyloidosis , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[16]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  R. Falk Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.

[18]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[19]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[20]  R. Falk,et al.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.

[21]  M. Skinner,et al.  Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.

[22]  G. Palladini,et al.  Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? , 2002, Heart.

[23]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[24]  H. Itoh,et al.  Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. , 1998, Journal of the American College of Cardiology.

[25]  R. Falk,et al.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.

[26]  R. Falk,et al.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.

[27]  J. Laragh,et al.  Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. , 1992, Journal of the American College of Cardiology.

[28]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  It Istituto Superiore di Sanit,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .

[30]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.